Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can computer alerts help doctors avoid kidney damage from drugs?

NCT ID NCT06264752

Knowledge-focused Sponsor: University of Pittsburgh Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study tested whether a computer system that alerts pharmacists about patients at risk for drug-related kidney injury can help doctors make safer medication decisions. The trial involved 698 hospitalized adults across eight hospitals. Pharmacists reviewed alerts and made recommendations to doctors, such as adjusting or stopping certain medications. The goal was to see if this approach reduces serious kidney complications.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this approach could reduce kidney damage and complications from medications in hospitalized patients.
What could go wrong
This is a completed study testing a decision-support system, not a new drug. Results may not apply to all hospitals or patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

698 people

The number who actually took part.

Started

Feb 2024

Finished

Jul 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Physician-subject Inclusion * Physicians employed at UPMC hospital systems * Attending physicians of record who care for patients across multiple units outside ICU/ED * Physician cares for 1 or more patient receiving a system alert identifying high-risk for AKI Patient-subject Inclusion * System alert identifying risk for AKI * Patient has attending physician who is participating in the randomized clusters * After initial patient inclusion, an individual patient will not be eligible for re-inclusion until after 90 days. Re-inclusion will only be allowed if a separate hospital admission/encounter occurs and only starting on day 91 Exclusion Criteria: Physician-subject Exclusion * Physicians of record who only care for ICU or ED patients * Physicians who primarily provide care for transplant (heart, kidney, liver, etc.) patients * Physicians who primarily provide consult services only (dermatology, rehabilitation, etc.) Patient-subject Exclusion • Patients with end stage renal disease on admission, baseline eGFR \<15, comfort measures only, or died before the intervention could be delivered

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Acute kidney injury are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

acute kidney injury Drug-Related Side Effects and Adverse Reactions

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Acute kidney injury

Contacts and locations

Locations

  • UPMC Altoona

    Altoona, Pennsylvania, 16601, United States

  • UPMC Horizon

    Farrell, Pennsylvania, 16121, United States

  • UPMC Jameson

    New Castle, Pennsylvania, 16105, United States

  • UPMC Magee

    Pittsburgh, Pennsylvania, 15213, United States

  • UPMC McKeesport

    McKeesport, Pennsylvania, 15132, United States

  • UPMC Presbyterian/Montefiore

    Pittsburgh, Pennsylvania, 15213, United States

  • UPMC Shadyside

    Pittsburgh, Pennsylvania, 15232, United States

  • UPMC Williamsport

    Williamsport, Pennsylvania, 17701, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.